Diabetes industry veteran joins Glucotrackβs Board to support bringing novel continuous blood glucose...
Completion of the novel epidural continuous glucose monitoring study confirms its potential for providing...
Rutherford, NJ, June 10, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (βGlucotrackβ or the...
Highly accurate continuous blood glucose monitor demonstrates Mean Absolute Relative Difference (MARD) of 4.7...
Promising results support the potential of epidural glucose monitoring for simplified disease management for...
1-for-5 reverse stock split to become effective as of the opening of trading onMay 20, 2024 Rutherford, NJ, May...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.